Bioavailability of endotracheal epinephrine in an ovine model of neonatal resuscitation.
Endotracheal epinephrine
Epinephrine concentration
Lung liquid
Neonatal resuscitation
Journal
Early human development
ISSN: 1872-6232
Titre abrégé: Early Hum Dev
Pays: Ireland
ID NLM: 7708381
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
27
09
2018
revised:
22
12
2018
accepted:
08
01
2019
pubmed:
20
1
2019
medline:
19
6
2019
entrez:
20
1
2019
Statut:
ppublish
Résumé
Distressed infants in the delivery room and those that have completed postnatal transition are both resuscitated according to established neonatal resuscitation guidelines, often with endotracheal (ET) epinephrine at the same dose. We hypothesized that ET epinephrine would have higher bioavailability in a post-transitional compared to transitioning newborn model due to absence of fetal lung liquid and intra-cardiac shunts. 15 term fetal (transitioning newborn) and 6 postnatal lambs were asphyxiated by umbilical cord and ET tube occlusion respectively. Lambs were resuscitated after 5 min of asystole. ET epinephrine (0.1 mg/kg) was administered after 1 min of positive pressure ventilation (PPV) and chest compressions, and repeated 3 min later, followed by intravenous (IV) epinephrine (0.03 mg/kg) every 3 min until return of spontaneous circulation (ROSC). Serial plasma epinephrine concentrations were measured. Peak plasma epinephrine concentrations were lower in transitioning newborns as compared to postnatal lambs: after a single ET dose (145.36 ± 135.5 ng/ml vs 553.54 ± 215 ng/ml, p < 0.01) and after two ET doses (443 ± 192.49 ng/ml vs 1406 ± 420.8 ng/ml, p < 0.01). The rates of ROSC with a single ET dose were similar in both groups (40% vs 50% in newborn and postnatal respectively, p > 0.99). There was a higher incidence of post-ROSC tachycardia and increased carotid blood flow in the postnatal group. In the postnatal period, ET epinephrine at currently recommended doses resulted in higher peak epinephrine concentrations, post-ROSC tachycardia and cerebral reperfusion without significant differences in incidence of ROSC. Further studies evaluating the optimal dose of ET epinephrine during the postnatal period are warranted.
Sections du résumé
BACKGROUND
Distressed infants in the delivery room and those that have completed postnatal transition are both resuscitated according to established neonatal resuscitation guidelines, often with endotracheal (ET) epinephrine at the same dose. We hypothesized that ET epinephrine would have higher bioavailability in a post-transitional compared to transitioning newborn model due to absence of fetal lung liquid and intra-cardiac shunts.
METHODS
15 term fetal (transitioning newborn) and 6 postnatal lambs were asphyxiated by umbilical cord and ET tube occlusion respectively. Lambs were resuscitated after 5 min of asystole. ET epinephrine (0.1 mg/kg) was administered after 1 min of positive pressure ventilation (PPV) and chest compressions, and repeated 3 min later, followed by intravenous (IV) epinephrine (0.03 mg/kg) every 3 min until return of spontaneous circulation (ROSC). Serial plasma epinephrine concentrations were measured.
RESULTS
Peak plasma epinephrine concentrations were lower in transitioning newborns as compared to postnatal lambs: after a single ET dose (145.36 ± 135.5 ng/ml vs 553.54 ± 215 ng/ml, p < 0.01) and after two ET doses (443 ± 192.49 ng/ml vs 1406 ± 420.8 ng/ml, p < 0.01). The rates of ROSC with a single ET dose were similar in both groups (40% vs 50% in newborn and postnatal respectively, p > 0.99). There was a higher incidence of post-ROSC tachycardia and increased carotid blood flow in the postnatal group.
CONCLUSIONS
In the postnatal period, ET epinephrine at currently recommended doses resulted in higher peak epinephrine concentrations, post-ROSC tachycardia and cerebral reperfusion without significant differences in incidence of ROSC. Further studies evaluating the optimal dose of ET epinephrine during the postnatal period are warranted.
Identifiants
pubmed: 30660015
pii: S0378-3782(18)30610-8
doi: 10.1016/j.earlhumdev.2019.01.006
pmc: PMC6402978
mid: NIHMS1518817
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-32Subventions
Organisme : NICHD NIH HHS
ID : R01 HD072929
Pays : United States
Organisme : NICHD NIH HHS
ID : R03 HD086531
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Circulation. 2015 Nov 3;132(18 Suppl 2):S543-60
pubmed: 26473001
N Engl J Med. 2004 Apr 22;350(17):1722-30
pubmed: 15102998
Clin Perinatol. 2012 Dec;39(4):843-55
pubmed: 23164182
Pediatrics. 2010 Nov;126(5):e1400-13
pubmed: 20956432
J Pediatr. 2017 Jun;185:232-236
pubmed: 28285754
Crit Care Med. 1999 Dec;27(12):2748-54
pubmed: 10628621
Resuscitation. 2013 Jan;84(1):108-13
pubmed: 22727945
J Vis Exp. 2018 Aug 15;(138):
pubmed: 30175999
Circulation. 2015 Nov 3;132(18 Suppl 2):S526-42
pubmed: 26473000
Biomed Res Int. 2014;2014:192769
pubmed: 24696844
Circulation. 2015 Oct 20;132(16 Suppl 1):S177-203
pubmed: 26472853
J Am Heart Assoc. 2017 Feb 18;6(2):
pubmed: 28214793
Clin Perinatol. 2006 Mar;33(1):153-60, ix
pubmed: 16533641
Crit Care Med. 1996 Oct;24(10):1695-700
pubmed: 8874308
Front Pediatr. 2017 May 01;5:97
pubmed: 28507983
Ann Emerg Med. 1991 Mar;20(3):230-4
pubmed: 1996815
Anesth Analg. 2001 Jun;92(6):1408-12
pubmed: 11375813
Pediatrics. 2006 Sep;118(3):1028-34
pubmed: 16950994
Circulation. 2015 Nov 3;132(18 Suppl 2):S444-64
pubmed: 26472995
Circulation. 1970 Feb;41(2):343-59
pubmed: 5412993
Pediatr Res. 1985 Jul;19(7):645-50
pubmed: 3839577
Anesth Analg. 1967 Mar-Apr;46(2):253-8
pubmed: 6066982
J Perinatol. 2017 Feb;37(2):172-176
pubmed: 27787506